Reproductive health

INVESTOR ALERT: Edelson Lechtzin LLP is Investigating Securities Fraud Claims on Behalf of Fulgent Genetics, Inc. (NASDAQ: FLGT) Shareholders

Retrieved on: 
Friday, September 23, 2022

A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Key Points: 
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • Investors who wish to discuss the lead plaintiff selection process should contact Edelson Lechtzin LLP, toll free at 1-844-696-7492, or by e-mail at [email protected] .
  • Background on the Fulgent Genetics, Inc. Securities Class Action
    Fulgent is a full-service genomic testing company built around a foundational technology platform.
  • For more information about the securities fraud class action and related litigation, please contact:

Evofem Announces Issuance of U.S. Patent Covering Phexxi® Composition of Matter

Retrieved on: 
Friday, September 23, 2022

SAN DIEGO, Sept. 23, 2022 /PRNewswire/ -- Evofem Biosciences (OTCPK: EVFM) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,439,610, which covers the composition of matter of Phexxi® (lactic acid, citric acid, potassium bitartrate).  

Key Points: 
  • 11,439,610, which covers the composition of matter of Phexxi (lactic acid, citric acid, potassium bitartrate).
  • "We are extremely pleased with the continued development of the Phexxi patent portfolio, which comprises more than 40 patents.
  • Top-line data from EVOGUARD, Evofem's registrational Phase 3 clinical trial evaluating Phexxi for these two potential new indications, are expected in mid-October.
  • Evofem now has the sole right in the United States to make, have made, market, and sell for any commercial purpose the composition of matter that comprises Phexxi.

XpresSpa Group Expands Retail Products for Women, Underscoring Company’s Commitment to Support Women’s Health and Wellness

Retrieved on: 
Wednesday, September 21, 2022

As part of this launch, the Company rolled out an expanded line of retail products dedicated to womens health including products in the personal hygiene, pregnancy prevention, reproductive health, first aid and wellness categories.

Key Points: 
  • As part of this launch, the Company rolled out an expanded line of retail products dedicated to womens health including products in the personal hygiene, pregnancy prevention, reproductive health, first aid and wellness categories.
  • We want to deliver solutions that inform and serve their evolving lifestyles and meet their specific health and wellness needs, said XpresSpa Group CEO Scott Milford.
  • We created the Womens Health Initiative to increase the Companys support for women and to provide enhanced education and access to health and wellness solutions for women on the go.
  • XpresSpa Group, Inc.(Nasdaq: XSPA) is a leading global health and wellness holding company operating four brands: XpresCheck,XpresSpa, Treat and HyperPointe.

Fertilab Barcelona: 8 out of 10 women who overcome cancer succeed in having a baby the following year

Retrieved on: 
Tuesday, September 20, 2022

However, we have experienced an increase in cases of gynaecological cancer among people of reproductive age and in childhood cancer.

Key Points: 
  • However, we have experienced an increase in cases of gynaecological cancer among people of reproductive age and in childhood cancer.
  • Recently, there has also been an exponential increase in cases of colon and lung cancer due to the increase in female smokers.
  • This is why the field of oncofertility toils to improve the reproductive health of patients who overcome cancer so that they can plan for a family once they have overcome the illness.
  • This trend means that the age of pregnancy and the age of cancer risk increasingly coincide, particularly after the age of 40.

P.volve Names Dr. Shannon DeVore to Clinical Advisory Board

Retrieved on: 
Tuesday, September 20, 2022

P.volve , the leader in evidence-based functional fitness for women, announced today that it has appointed Dr. Shannon M. DeVore to its Clinical Advisory Board as MD, Reproductive Endocrinologist.

Key Points: 
  • P.volve , the leader in evidence-based functional fitness for women, announced today that it has appointed Dr. Shannon M. DeVore to its Clinical Advisory Board as MD, Reproductive Endocrinologist.
  • We are proud to announce Dr. Shannon DeVores appointment to our Clinical Advisory Board, said Julie Cartwright , president of P.volve.
  • These programs, with the approval of P.volves Clinical Advisory Board, are designed to address womens fitness needs as their bodies move through each stage of pregnancy.
  • Dr. DeVore joins current Clinical Advisory Board members Dr. Amy Price Hoover (Doctor of Physical Therapy); Dr. Nima Alamdari (Doctor of Physiology); and Dr. Suman Tewari (Doctor of Gynecology).

Illumina Genomics Forum to Feature Nobel Laureate Frances Arnold as part of Distinguished Panel on How the Genomics Revolution Is Transforming Patient Care

Retrieved on: 
Monday, September 19, 2022

SAN DIEGO, Sept. 19, 2022 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will convene a panel titled "Clinical Genomics Is Now. Are You Ready?" at its inaugural Illumina Genomics Forum (IGF), moderated by Nobel laureate and chemical engineer Frances Arnold of the California Institute of Technology. The September 28 roundtable will focus on genomics' role in transforming human health and the next steps in bridging research and clinical genomics.

Key Points: 
  • at its inaugural Illumina Genomics Forum (IGF), moderated by Nobel laureate and chemical engineer Frances Arnold of the California Institute of Technology.
  • The September 28 roundtable will focus on genomics' role in transforming human health and the next steps in bridging research and clinical genomics.
  • "We are honored to have Nobel laureate Frances Arnold join our remarkable lineup of genomics and health care leaders to guide this important discussion demonstrating the spectrum of clinical utility now and the exciting road ahead," said Kathryne Reeves, chief marketing officer of Illumina.
  • To learn more,visit illumina.com and connect with us on Twitter , Facebook , LinkedIn , Instagram , and YouTube .

Inventor of the Year Awarded to Developer of Phexxi®

Retrieved on: 
Monday, September 19, 2022

SAN DIEGO, Sept. 19, 2022 /PRNewswire/ -- Evofem Biosciences (OTCPK: EVFM) is pleased to congratulate University of Illinois Chicago (UIC) Professor Emeritus Donald Waller, Ph.D., on his recognition as Inventor of the Year for his role in developing novel therapeutics for the improvement of women's health, including Phexxi® (lactic acid, citric acid, potassium bitartrate).

Key Points: 
  • "We started by looking at natural defenses both against pregnancy and against pathogens, such as gonorrhea and other STIs.
  • Phexxi, the first innovation in the contraceptive category in decades, was approved by the FDA in 2020 for prevention of pregnancy.
  • Since Phexxi's initial launch, over 100,000 women have been prescribed Phexxi by nearly 21,000 health care providers.
  • Positive study outcomes would enable regulatory submissions and potential approval for prevention of these sexually transmitted infections (STIs) in 2023.

Large Commercial Payer Adds Phexxi® to Formulary for Standard Plans Nationwide

Retrieved on: 
Friday, September 16, 2022

SAN DIEGO, Sept. 16, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCPK: EVFM) today announced another new insurance win that gives millions of additional women access to Phexxi® (lactic acid, citric acid, potassium bitartrate) for the prevention of pregnancy.

Key Points: 
  • "Evofem's diligent efforts to expand access to Phexxi nationwide continue to pay off," said Saundra Pelletier, Chief Executive Officer of Evofem.
  • "We are thrilled that another highly respected national-level payer is now covering Phexxi, allowing women to fill their prescriptions immediately.
  • Evofem consistently engages with these payers to ensure they comply with these guidelines in covering Phexxi.
  • If you have a history of urinary tract problems that keep coming back, you should not use Phexxi.

Evofem Announces Successful Debt Restructuring

Retrieved on: 
Friday, September 16, 2022

SAN DIEGO, Sept. 16, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCPK: EVFM) today announced the successful restructuring of its debt, providing forbearance from its debtholders related to all existing events of default.

Key Points: 
  • SAN DIEGO, Sept. 16, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCPK: EVFM)today announced the successful restructuring of its debt, providing forbearance from its debtholders related to all existing events of default.
  • "This debt restructuring removes the overhang created by the Nasdaq delisting last month while securing ongoing forbearance from current defaults," said Saundra Pelletier, Evofem's Chief Executive Officer.
  • In addition to the forbearance from all the Company's debtholders, other terms of the restructuring arrangements include:
    All holders of junior unsecured debt obligations have exchanged these obligations into rights to acquire Evofem's common stock.
  • In addition, the remaining unsecured creditor, Adjuvant Capital, exchanged 10% of its unsecured debt obligations into rights to acquire Evofem's common stock.

QIAGEN Adds New Assays With CE-IVD Certification for NeuMoDx Integrated PCR System

Retrieved on: 
Thursday, September 15, 2022

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its comprehensive NeuMoDx assay menu for organ transplant-associated viruses.

Key Points: 
  • QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its comprehensive NeuMoDx assay menu for organ transplant-associated viruses.
  • The new assays support QIAGENs strategy of expanding the menu of tests available for use on the NeuMoDx 96 and 288 Molecular Systems.
  • The assay adds to the broad portfolio that QIAGEN offers to address all testing needs around monkeypox.
  • QIAGEN remains committed to responding to the COVID-19 endemic by preparing to launch a new multiple-target test: NeuMoDx FluA/FluB/RSV/SARS-CoV-2 Assay with a new dual-target SARS-CoV-2 design.